ABSTRACT Nedocromil sodium is a pyranoquinoline derivative that has been developed for the treatment of asthma. We report the results of a double blind randomised study of the effect of two doses of nedocromil sodium (2 and 4 mg) and matched placebo, delivered by metered dose pressurised aerosol, on bronchoconstriction induced by sulphur dioxide in six asthmatic subjects. Nedocromil sodium had no effect on baseline lung function. The magnitude of sulphur dioxide induced bronchoconstriction monitored by partial forced expiratory flow at 30% of reference vital capacity was significantly inhibited by nedocromil sodium 4 mg (p < 0 05) but not by 2 mg. The maximum changes after placebo and after nedocromil 2 mg and 4 mg were -44-7, -32-7, and -11 8 1 min-'. The area under the curve monitoring the effect over 6 minutes was significantly inhibited by both doses to the same extent, the mean changes after placebo and after nedocromil 2 mg and 4 mg being -349-3, -31 2, and 44-6 1. Dyspnoea was monitored by visual analogue scale and showed a significant reduction over 6 minutes with both doses of nedocromil. After placebo and after nedocromil 2 mg and 4 mg the mean maximum changes were 31 5, 13 7, and 15 7 mm, and the mean changes in area under the visual analogue scale-time curve were 289, 194, and 151 mm.min respectively.
Nedocromil sodium, the disodium salt of a paranoquinoline dicarboxylic acid, has been developed for the treatment of asthma. Nedocromil sodium protects against exercise induced asthma,' antigen induced bronchoconstriction,2 antigen induced nasal obstruction,3 and bronchoconstriction caused by nonspecific stimuli.4 When administered four times daily for one month, it improves the control of bronchial asthma. 5 The profile of action of nedocromil sodium is similar to that of sodium cromoglycate. Since sodium cromoglycate protects against bronchoconstrictor responses to sulphur dioxide6 we have investigated whether nedocromil sodium 2 or 4 mg confers similar protection against sulphur dioxide induced bronchoconstriction when compared with matched placebo. It seems likely that part at least of sulphur dioxide induced bronchoconstriction depends on neural mechanisms since it is reduced by cholinergic antagonists,7 and in animals sulphur dioxide stimulates afferent fibres in the airways. 8 
Discussion
Inhaled nedocromil sodium significantly inhibited the magnitude and duration of bronchoconstriction and breathlessness after inhalation of sulphur dioxide. The 4 mg dose had a greater protective effect than the 2 mg dose against the maximum change in VP30; but the two doses were equally effective in limiting the duration of change in VP30 and dyspnoea score.
Although some workers have been able to construct a three point dose-response curve for sulphur dioxide,'3 like others14 we were unable to do this with our system owing to development of tachyphylaxis to sulphur dioxide. We therefore observed the effect of nedocromil sodium on the bronchoconstrictor response to a single concentration of sulphur dioxide. This protocol also allowed us to examine the effect of nedocromil sodium on the duration of bronchoconstriction. To detect any change in the subject's sensitivity to sulphur dioxide during the course of this study a final control day as well as a placebo day was incorporated. This showed that bronchoconstrictor responses to fixed concentrations of sulphur dioxide were consistent for each subject.
A dyspnoea score was incorporated because sulphur dioxide inhalation provoked a retrosternal discomfort and feeling of breathlessness that appeared to be out of proportion to the degree of bronchoconstriction when compared with other nonspecific bronchial challenges such as histamine and methacholine. We therefore considered it important to monitor the subjective assessment of dyspnoea using a visual analogue scale.'5 The mechanism by which nedocromil inhibits sulphur dioxide induced bronchoconstriction is uncertain. Nedocromil sodium inhibits the change in lung mechanics produced by antigen challenge in Ascaris sensitive monkey in vivo, and inhibits histamine release from mucosal mast cells in vitro with a much greater potency than sodium cromoglycate. 6 Sodium cromoglycate, however, which has a profile of action similar to that of nedocromil sodium, also inhibits afferent nerve activity in animals,'7 so possibly nedocromil sodium is acting by blocking the effect of sulphur dioxide on afferent discharge. The reduction of dyspnoea score by nedocromil sodium provides some support for an effect on afferent nerve endings.
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